Reduction of CXCR3+CCR6+ CD4+ T Cells and IL‐17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy

Addison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D Inman · 2026

Read Reduction of CXCR3+CCR6+ CD4+ T Cells and IL‐17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy by Addison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D Inman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13525373.txt.

Description

Five authors report a study dated two thousand twenty-six on a form of inflammatory arthritis of the spine. The condition is axial spondyloarthritis. Some patients do not respond to a first biologic drug, secukinumab, and doctors must pick the next drug with little guidance on who will benefit.

The team re-read immune data from eighteen patients who had not responded. Eight were switched to a different class of biologic, and ten had their dose raised. Falls in two sets of helper T cells during the first drug marked the patients who later did well. Disease activity was checked at week twenty-four to judge the response.

Catalog record

CREATORAddison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D Inman
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13525373

Browse the full library · About the Tower of Babel